

# Ralinepag

**Catalog No: tcsc0012350**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1187856-49-0

**Formula:**

$C_{23}H_{26}ClNO_5$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 125 mg/mL (289.41 mM; Need ultrasonic and warming)

**Alternative Names:**

APD811

**Observed Molecular Weight:**

431.91


## Product Description

Ralinepag is a potent, orally bioavailable and non-prostanoid **prostacyclin (IP) receptor** agonist, with **EC<sub>50</sub>s** of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.

IC<sub>50</sub> & Target: EC<sub>50</sub>: 8.5 nM (Human IP receptor), 530 nM (Rat IP receptor), 850 nM (Human DP1 receptor)<sup>[1]</sup>

**In Vitro:** Ralinepag is a potent non-prostanoid prostacyclin receptor agonist, with EC<sub>50</sub>s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively. Ralinepag (5c) has potent receptor binding affinity at prostaglandin receptor, with K<sub>i</sub>s of 1.2 nM, 3 nM, 76 nM, and 256 nM for monkey, human, rat, and dog IP receptor (ligand, [<sup>3</sup>H]-iloprost), and 2.6 μM, 9.6 μM, 610 nM, 143 nM, and 678 nM for human DP1, EP1, EP2, EP3v6 and EP4 receptors (ligand, [<sup>3</sup>H]-PGE<sub>2</sub>), respectively. Moreover, Ralinepag shows no effect on cytochrome P450 enzymes (IC<sub>50</sub> > 50 μM for CYPs 1A2, 2D6, 3A4 2C8, 2C9, and 2C19) or hERG channel functional activity in a patch clamp assay (IC<sub>50</sub> > 30 μM). Ralinepag also inhibits the ADP-induced human platelet aggregation, with an IC<sub>50</sub> of 38 nM<sup>[1]</sup>.

**In Vivo:** Ralinepag (30 mg/kg, p.o.) markedly reduces the monocrotaline (MCT)-induced increase in pulmonary arterial pressure and pulmonary vessel wall thickness in rats<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!